StockNews.com Begins Coverage on Akari Therapeutics (NASDAQ:AKTX)

Analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Up 3.1 %

NASDAQ:AKTX opened at $1.33 on Wednesday. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40. The firm’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $2.44.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.